NCT05353686View on ClinicalTrials.gov

A Trial Investigating the Effect of 4 Weeks Dosing of XEN-D0501 on Blood Glucose Reduction in Patients With Diabetes

PHASE2CompletedINTERVENTIONAL
Enrollment

54

Participants

Timeline

Start Date

February 25, 2019

Primary Completion Date

December 19, 2019

Study Completion Date

December 19, 2019

Conditions
EfficacySafetyPharmacokineticsDiabetes Mellitus, Type 2
Interventions
DRUG

Placebo

Subjects in the placebo arm will receive an oral tablet containing no active drug twice daily

DRUG

XEN-D0501

Subjects in the XEN-D0501 arm will receive an oral tablet containing 4 mg/tablet of IMP twice daily

Trial Locations (10)

LT-55201

Kristavita, JSC, Jonava

LT-44175

"Auki sveikas (A klinika)", Kaunas

LT-49449

Saules seimos medicinos centras, JSC, Kaunas

LT-51270

Kaunas City Polyclinic / Dainava Outpatient Clinic, Kaunas

LT-57164

Kedainiai Hospital / Outpatient Department, Kėdainiai

LT-92304

A. Navickas Outpatient Clinic, Klaipėda

LT-04318

Karoliniskiu Outpatient Clinic, Vilnius

LT-08661

Vilnius University Hospital Santaros Clinics / Family Center Department, Vilnius

Vilnius University Hospital Santaros Clinics, Vilnius

LT-09112

Vaidotas Urbanavicius Sole Proprietary Enterprise, Vilnius

Sponsors

Lead Sponsor

Pila Pharma

Collaborators (1)

Biomapas
All Listed Sponsors
collaborator

Biomapas

UNKNOWN

lead

Pila Pharma

INDUSTRY

NCT05353686 - A Trial Investigating the Effect of 4 Weeks Dosing of XEN-D0501 on Blood Glucose Reduction in Patients With Diabetes | Biotech Hunter | Biotech Hunter